fda pulling tirzepatide Is Approved? FDA Declares End to Tirzepatide

Cannot redeclare control with same name "grid_1_cta_shadow_hover_box_shadow"

A safe and effective approach to weight loss using GLP-1 medications under medical supervision

While the study found no significant differences in the primary efficacy endpoint (time to first tolerated meal), the ipamorelin group showed reduced median time to first tolerated meal (25.3 hours versus 32.6 hours in placebo) and had fewer overall treatment-emergent adverse events (87.5% versus 94.8%)

Similarly, a 2023 review published in Frontiers in Immunology found that GLP-1 receptor agonists reduced pro-inflammatory cytokines and oxidative stress markers across multiple tissues

These benefits cut heart risks beyond just lowering cholesterol numbers